You can buy or sell TTNP and other stocks, options, ETFs, and crypto commission-free!
Titan Pharmaceuticals, Inc. Common Stock, also called Titan Pharmaceuticals, is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Read More Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2018 financial results will be released after market close on Monday, April 1, 2019. Titan will host a live conference call to discuss the financial results and provide a general business review the following day, April 2, 2019, at 8:30 a.m. ET / 5:30 a.m. PT. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe DeVarney, Ph.D., exec...
Seeking AlphaFeb 25
Titan Pharmaceuticals teams up with AllianceRX Walgreens Prime; shares up 65% premarket
Titan Pharmaceuticals (NASDAQ:TTNP) is up 65% premarket on executing a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, for opioid use disorder (OUD) in eligible patients.